GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Immunovia AB (OSTO:IMMNOV) » Definitions » Cyclically Adjusted PS Ratio

Immunovia AB (OSTO:IMMNOV) Cyclically Adjusted PS Ratio : 16.90 (As of May. 09, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Immunovia AB Cyclically Adjusted PS Ratio?

As of today (2025-05-09), Immunovia AB's current share price is kr0.338. Immunovia AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was kr0.02. Immunovia AB's Cyclically Adjusted PS Ratio for today is 16.90.

The historical rank and industry rank for Immunovia AB's Cyclically Adjusted PS Ratio or its related term are showing as below:

OSTO:IMMNOV' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 12.65   Med: 19.75   Max: 26.95
Current: 17.48

During the past years, Immunovia AB's highest Cyclically Adjusted PS Ratio was 26.95. The lowest was 12.65. And the median was 19.75.

OSTO:IMMNOV's Cyclically Adjusted PS Ratio is ranked worse than
96.95% of 131 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.08 vs OSTO:IMMNOV: 17.48

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Immunovia AB's adjusted revenue per share data for the three months ended in Dec. 2024 was kr0.003. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is kr0.02 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Immunovia AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Immunovia AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovia AB Cyclically Adjusted PS Ratio Chart

Immunovia AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 34.71

Immunovia AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 34.71

Competitive Comparison of Immunovia AB's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Immunovia AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunovia AB's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Immunovia AB's Cyclically Adjusted PS Ratio falls into.


;
;

Immunovia AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Immunovia AB's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.338/0.02
=16.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunovia AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Immunovia AB's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.003/132.9872*132.9872
=0.003

Current CPI (Dec. 2024) = 132.9872.

Immunovia AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.000 100.541 0.000
201412 0.000 100.225 0.000
201506 0.000 99.995 0.000
201512 0.000 100.276 0.000
201603 0.000 100.751 0.000
201606 0.002 101.019 0.003
201609 0.000 101.138 0.000
201612 0.003 102.022 0.004
201703 0.001 102.022 0.001
201706 0.002 102.752 0.003
201709 0.001 103.279 0.001
201712 0.001 103.793 0.001
201803 0.003 103.962 0.004
201806 0.001 104.875 0.001
201809 0.002 105.679 0.003
201812 0.002 105.912 0.003
201903 0.002 105.886 0.003
201906 0.004 106.742 0.005
201909 0.002 107.214 0.002
201912 0.001 107.766 0.001
202003 0.000 106.563 0.000
202006 0.004 107.498 0.005
202009 0.001 107.635 0.001
202012 0.003 108.296 0.004
202103 0.003 108.360 0.004
202106 0.001 108.928 0.001
202109 0.008 110.338 0.010
202112 0.006 112.486 0.007
202203 0.004 114.825 0.005
202206 0.002 118.384 0.002
202209 0.008 122.296 0.009
202212 0.008 126.365 0.008
202303 0.011 127.042 0.012
202306 0.005 129.407 0.005
202309 0.011 130.224 0.011
202312 0.003 131.912 0.003
202403 0.002 132.205 0.002
202406 0.001 132.716 0.001
202409 0.003 132.304 0.003
202412 0.003 132.987 0.003

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Immunovia AB  (OSTO:IMMNOV) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Immunovia AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Immunovia AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunovia AB Business Description

Traded in Other Exchanges
Address
Medicon Village, Scheelevagen 8, Lund, SWE, 223 63
Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The company is currently developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer.

Immunovia AB Headlines

No Headlines